Snowball logo
logo
ABBV_logo

AbbVie Inc

$250.52+$1.76ย  (0.71%)
AbbVie's financial performance over the past year ...
View AAPL example
Estimate
P/E
70.8
EPS
3.54
Beta
0.28
Growth
Revenue, YoY
10.16%
Net income, YoY
285.82%
FCF, YoY
-24.22%
Forecast
P/E (FWD)
15.3
EPS (FWD)
16.363
Dividends
Dividend yield
2.76%
Annual payout
$6.92
Next ex. div date
October 15, 26
Payout
189.53%
Div.growth, 5y
5.88%
Dividend growth streak
12 y
Div.rating
About the company
Ticker
ABBV
ISIN
US00287Y1091
Country
United States of America
Sector (GICS)
Healthcare
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions. In addition, the company offers Ozurdex for visual impairment; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; and other eye care products, including Refresh/Optive, Xen, Durysta, and Restasis. Further, it provides Mavyret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Frequently asked questions

What sector does AbbVie Inc (ABBV) operate in?

AbbVie Inc belongs to the Healthcare sector and operates in the Drug Manufacturers - General industry.

What is AbbVie Inc (ABBV) current stock price?

As of the latest data, AbbVie Inc stock price is $250.52, with a previous close of $248.76. AbbVie Inc gained $1.76 in the last trading session, representing a 0.71% increase.

What is AbbVie Inc (ABBV) current market capitalization?

AbbVie Inc market cap is approximately 442.70 billion.

What is AbbVie Inc (ABBV) Earnings Per Share (EPS)?

The trailing EPS is $3.54, and the forward EPS is $16.36.

What is AbbVie Inc (ABBV) Price-to-Earnings (P/E) ratio?

AbbVie Inc current P/E ratio is 70.77, with a forward P/E of 15.31.

What is AbbVie Inc (ABBV) EBITDA?

AbbVie Inc EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is 6.72 billion.

Does AbbVie Inc (ABBV) pay dividends?

Yes. AbbVie Inc pays quarterly dividends with an annualized yield of 2.76% and an estimated annual payout of $6.92 per share.

When is the next ex-dividend date for AbbVie Inc (ABBV)?

The next ex-dividend date is scheduled for October 15, 2026.

How did AbbVie Inc (ABBV) perform in its most recent earnings report?

In the last report (June 30, 2026), AbbVie Inc posted an EPS surprise of 0.27% and a revenue surprise of 1.4%.

What is AbbVie Inc (ABBV) beta (volatility) score?

AbbVie Inc has a beta of 0.280, indicating lower volatility than the overall market.